Home > Compound List > Product Information
Alfentanil_Molecular_structure_CAS_71195-58-9)
Click picture or here to close

Alfentanil

Catalog No. DB00802 Name DrugBank
CAS Number 71195-58-9 Website http://www.ualberta.ca/
M. F. C21H32N6O3 Telephone (780) 492-3111
M. W. 416.51718 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 681

SYNONYMS

IUPAC name
N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-1,2,3,4-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide
IUPAC Traditional name
alfentanil
Brand Name
Alfenta
Synonyms
Alfentanilum [INN-Latin]
Alfentanyl

DATABASE IDS

PubChem CID 51263
PubChem SID 46505618
CAS Number 71195-58-9

PROPERTIES

Hydrophobicity(logP) 0.2
Solubility 34.6 mg/L

DETAILS

Description (English)
Item Information
Drug Groups illicit; approved
Description A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. [PubChem]
Indication For the management of postoperative pain and the maintenance of general anesthesia.
Pharmacology Alfentanil is a synthetic opioid analgesic. Alfentanil interacts predominately with the opioid mu-receptor. These mu-binding sites are discretely distributed in the human brain, spinal cord, and other tissues. In clinical settings, alfentanil exerts its principal pharmacologic effects on the central nervous system. Its primary actions of therapeutic value are analgesia and sedation. Alfentanil may increase the patient's tolerance for pain and decrease the perception of suffering, although the presence of the pain itself may still be recognized. In addition to analgesia, alterations in mood, euphoria and dysphoria, and drowsiness commonly occur. Alfentanil depresses the respiratory centers, depresses the cough reflex, and constricts the pupils.
Toxicity Symptoms of overexposure include characteristic rigidity of the skeletal muscles, cardiac and respiratory depression, and narrowing of the pupils.
Affected Organisms
Humans and other mammals
Biotransformation The liver is the major site of biotransformation.
Absorption For intravenous injection or infusion only.
Half Life 90-111 minutes
Protein Binding 92%
Elimination Only 1.0% of the dose is excreted as unchanged drug; urinary excretion is the major route of elimination of metabolites.
Distribution * 0.4 to 1 L/kg
Clearance * 5 mL/kg/min
External Links
Wikipedia
RxList

REFERENCES